source
- The FDA was all in on AI. Will that change?High-level turnover has introduced uncertainty about how quickly the FDA’s agency-wide AI strategy will move forward.
- Apnimed eyes up to $160M IPO to prep for sleep apnea drug launchIf the offering closes, Apnimed will join the 2026 IPO class that has already far surpassed last year’s total.